How I Treat Patients With Progressive Myelofibrosis
Ruben A. Mesa, MD, UT Health Cancer Center
Friday, September 8, 2017 8:00 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Myelofibrosis, whether primarily originating from a central thrombocythemia or polycythemia vera, is by nature a progressive myeloid neoplasm with worsening cytopenias, splenomegaly symptoms, and potential progression to acute myeloid leukemia. The approval of ruxolitinib has been a tremendous benefit of two patients with myelofibrosis having extended survival and improved splenomegaly and symptoms; however, unmet needs exist. Dr. Mesa will take a case-based approach to different progressive scenarios these patients can face and how to overcome them with current investigational therapies, off study regimens, off study pharmacologic regimens, non-pharmacologic interventions, and allogenic stem cell transplantation. The most recent information regarding investigational agents will be woven into a discussion that balances against other options these patients have that clinicians may well be able to utilize.
About the Speaker
Ruben A. Mesa, MD, is Director of the UT Health Cancer Center. He is a physician investigator with a career focus on developing new therapies for patients with myeloproliferative neoplasms and seeking to better quantify the symptom burden these patients face, and as well as improving their quality of life. He has been lead investigator or co-lead investigator in more than 60 clinical trials throughout his career, is a co-lead investigator of the clinical trial arm of the NCI funded MPD Research Consortium, and is an inaugural panel chair for the NCCN Guideline Panel on myeloproliferative neoplasms.
back to top